News

PBM will have two representatives on Xalud’s Board of Directors and will also provide operational support to the Company. Xalud Therapeutics is an IND-stage platform gene therapy company

The results were presented in New York City at Stealth’s second Mitochondrial Science and Medicine Series symposium focused on mitochondria’s role in ophthalmology. ReVIEW, a clinical study of

The ARMOR3-SV trial is being carried out for mCRPC patients whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that

The acquisition also creates the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities. The deal was completed through a merger of

Currently, Maruishi is applying for a manufacture and marketing license for Remifentanil injection, which is widely used as an opioid analgesic (µ-opioid receptor agonist) to manage general anaesthesia.

Around 84 subjects with late-prodromal or early-manifest HD will be included in the Phase III SIGNAL trial. The trial will be performed with the assistance of the Huntington

In the trial, patients received 12 weeks of Viekirax+ Exviera without ribavirin (RBV) and the results showed 100% sustained virologic response at 12 weeks post-treatment (SVR12) in these

CDC’s Advisory Committee recommend that decisions to vaccinate adolescents and young adults of this age group against serogroup B meningococcal (MenB) disease should be made at the individual

The results showed that CPX-351 produced a relative improvement in induction response rate of 43.2% (47.7% for CPX-351 vs. 33.3% for the 7+3 regimen). Data on overall survival,